Augmenting CAR T Cells with PD-1 Blockade.
For patients with B-cell malignancies who experience poor initial responses to chimeric antigen receptor T-cell therapy, the addition of immune checkpoint blockade may prove beneficial, according to clinical reports presented at the 2018 American Society of Hematology Annual Meeting.